Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: A cost-effectiveness analysis

BMC Medicine

Volumn 7, Issue , 2009, Pages

  Kulasingam, Shalini L ^a,b,e   Rajan, Raghu ^c   St Pierre, Yvan ^c   Atwood, C Victoria ^c,d   Myers, Evan R ^a,b   Franco, Eduardo L ^c  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANADA; CANCER SCREENING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; EMERGENCY HEALTH SERVICE; FALSE POSITIVE RESULT; FEMALE; HUMAN; LIFE EXPECTANCY; PAPANICOLAOU TEST; SENSITIVITY AND SPECIFICITY; STRATEGIC PLANNING; UTERINE CERVIX CANCER; WART VIRUS; ADOLESCENT; COST BENEFIT ANALYSIS; ECONOMICS; MASS SCREENING; METHODOLOGY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ADULT; ALBERTA; CERVIX UTERI; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MASS SCREENING; NEWFOUNDLAND AND LABRADOR; ONTARIO; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 71049154590     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-7-69     Document Type: Article

References (35)

1. Screening for Cervical Cancer. , http://www.hc-sc.gc.ca/hl-vs/alt_formats/pacrb-dgapcr/pdf/iyh-vsv/diseas es-maladies/cervical-eng.pdf
2. Health Canada Cervical cancer screening in Canada: 1998 Surveillance Report. 2002,
3. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000, 9(9):945-951.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
5. Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 2003, 95(6):E2.
6. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007, 104(1):232-246. 10.1016/j.ygyno.2006.08.053, 17084886.
7. Stuart G, Taylor G, Bancej CM, Beaulac J, Colgan T, Franco EL, Kropp RY, Lotocki R, Mai V, McLachlin CM. Report of the 2003 pan-Canadian forum on cervical cancer prevention and control. J Obstet Gynaecol Can 2004, 26(11):1004-1028.
8. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357(16):1579-1588. 10.1056/NEJMoa071430, 17942871.
9. Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, Franco EL. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006, 119(3):615-623. 10.1002/ijc.21897, 16572425.
10. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000, 151(12):1158-1171.
11. Kulasingam SL, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K, Melnikow J, Washington AE, Sawaya GF. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol 2006, 107(2 Pt 1):321-328.
12. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc 2008, 6:4. 2290741, 18279515, 10.1186/1478-7547-6-4.
13. Richardson H, Abrahamowicz M, Tellier PP, Kelsall G, du Berger R, Ferenczy A, Coutlee F, Franco EL. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1149-1156. 10.1158/1055-9965.EPI-04-0230, 15894665.
14. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlee F, Franco EL. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003, 12(6):485-490.
15. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003, 168(4):421-425. 143547, 12591782.
16. Sellors JW, Karwalajtys TL, Kaczorowski JA, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ 2002, 167(8):871-873. 128399, 12406945.
17. Statistics Canada Canadian Community Health Survey, Cycle 2.1 Public Use Microdata file. Catalogue no. 82M0013X. Ottawa. Released January 24th, 2005.
18. Statistics Canada Profile of the Canadian population by age and sex: Canada ages. Catalogue no. 96F0030XIE2001002. Ottawa. Modified December 8, 2003.
19. National Cancer Institute Surveillance, Epidemiology, End Results (SEER) Cancer Statistics Review, 1973-1994. NIH Pub. No. 97-2789 2005, , http://seer.cancer.gov/csr/1973_1994/
20. Miller AB, Anderson G, Brisson J, Laidlaw J, Le Pitre N, Malcolmson P, Mirwaldt P, Stuart G, Sullivan W. Report of a National Workshop on Screening for Cancer of the Cervix. CMAJ 1991, 145(10):1301-1325. 1335946, 1933712.
21. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002, 288(14):1749-1757. 10.1001/jama.288.14.1749, 12365959.
22. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, (31):14-19.
23. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007, 335(7609):28. 1910655, 17517761, 10.1136/bmj.39196.740995.BE.
24. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119(5):1095-1101. 10.1002/ijc.21955, 16586444.
25. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132(10):810-819.
26. Government of Alberta Alberta Health Care Insurance Plan, Alberta Health and Wellness, Schedule of Medical Benefits, Part B: Medical Procedure List. 2007,
27. Government of Newfoundland and Labrador Medical Care Plan Payment Schedule. 2005,
28. Government of Ontario Ministry of Health and Long Term Care Schedule of Benefits, Physician Services Under the Health Insurance Act. 2005,
29. Government of Ontario Ministry of Health and Long Term Care Costing Analysis (CAT) Tool. 2007,
30. Canadian Institute for Health Information Hospital Financial Performance Indicators by Health Region, 2004-2005. 2006,
31. Brisson M, Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25(29):5399-5408. 10.1016/j.vaccine.2007.04.086, 17561316.
32. Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007, 27(4):414-422. 10.1177/0272989X07302128, 17585005.
33. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008, 100(5):308-320. 10.1093/jnci/djn019, 18314477.
34. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006, 24(Suppl 3). S3/171-177.
35. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008, 26(Suppl 1):A16-23. 10.1016/j.vaccine.2007.11.069, 18642468.